Rentschler opens GMP fill/finish facility in Austria

By Staff Reporter

- Last updated on GMT

(Image: Getty/PeterHermesFurian)
(Image: Getty/PeterHermesFurian)

Related tags: Austria, CDMO

Aseptic fill/finish contractor Rentschler Fill Solutions inaugurated the new facility in Austria’s eastern town of Rankweil.

Rentschler Fill Solutions GmbH opened the plant for the aseptic filling and freeze-drying of drug products intended for the European market.

The contract development and manufacturing organisation (CDMO) broke ground in Rankweil, Austria, in 2016. It received good manufacturing practice (GMP) certification and a European pharmaceutical manufacturing license from Austrian regulators in August 2018.

The company expects to receive US Food and Drug Administration (FDA) approval for the site in 2019.

“Together, we have successfully created an operational pharmaceutical business from scratch in record time,” ​said managing director, Reinhold Elsaesser, at the inauguration last week.

“We are now ready to help our clients bring unique active pharmaceutical ingredients to a global market. Very few companies in our region have this capability,” ​he added.

Rentschler Fill Solutions employs 59 employees and expects to increase headcount to 100 within the next two years.

In May of this year, the CDMO announced a service agreement​ with US-based Ultragenyx Pharmaceutical for commercial production.

According to the deal, Ultragenyx transferred fill/finish activities for injectable recombinant protein, Mepsevii (vestronidase alfa), from Rentschler Biopharma’s facility in Germany, to Rentschler Fill Solutions in Austria. The separate Rentschler companies are both owned by the Rentschler family.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more